Ramelteon
- Generic Name
- Ramelteon
- Brand Names
- Rozerem
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 196597-26-9
- Unique Ingredient Identifier
- 901AS54I69
- Background
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
- Indication
用于失眠症，特别适用于治疗难以入睡型失眠症。
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Ramelteon for Insomnia Comorbid With Asthma
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 2
- Registration Number
- NCT00869167
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 378
- Registration Number
- NCT00755508
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 472
- Registration Number
- NCT00755495
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 259
- Registration Number
- NCT00756002
Clinical Management of Neuropathic Pain With Ramelteon
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT00753623
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 3
- Registration Number
- NCT00745030
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
A Study of a Melatonin Receptor Agonist to Prevent Migraine
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT00739024
- Locations
- 🇺🇸
Swedish Pain and Headache Center, Seattle, Washington, United States
Efficacy of Ramelteon in Adults With Chronic Insomnia
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1081
- Registration Number
- NCT00672724
Efficacy of Ramelteon on Transient Insomnia in Healthy Adults
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 289
- Registration Number
- NCT00671398
Ramelteon in Adults With Chronic Insomnia
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2012-11-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 848
- Registration Number
- NCT00671567
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath